Amanda Fortes Francisco

Dr. Amanda Fortes Francisco

London School of Hygiene & Tropical Medicine, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
MLMichael D. Lewis
Michael D. Lewis
SJShiromani Jayawardhana
Shiromani Jayawardhana
MTMartin Taylor
Martin Taylor
ECEric Chatelain
Eric Chatelain
JKJohn Kelly
John Kelly
The antifungal drug posaconazole has shown significant activity against Trypanosoma cruzi in vitro and in experimental murine models. Despite this, in a recent clinical trial it displayed limited curative potential. Drug testing is problematic in experimental Chagas disease because of difficulties in demonstrating sterile cure, particularly during the chronic stage of infection when parasite burden is extremely low and tissue distribution is ill defined. To better assess posaconazole efficacy against acute and chronic Chagas disease, we have exploited a highly sensitive bioluminescence imaging system which generates data with greater accuracy than other methods, including PCR-based approaches. Mice inoculated with bioluminescent T. cruzi were assessed by in vivo and ex vivo imaging, with cyclophosphamide-induced immunosuppression used to enhance the detection of relapse. Posaconazole was found to be significantly inferior to benznidazole as a treatment for both acute and chronic T. cruzi infections. Whereas 20 days treatment with benznidazole was 100% successful in achieving sterile cure, posaconazole failed in almost all cases. Treatment of chronic infections with posaconazole did however significantly reduce infection-induced splenomegaly, even in the absence of parasitological cure. The imaging-based screening system also revealed that adipose tissue is a major site of recrudescence in mice treated with posaconazole in the acute, but not the chronic stage of infection. This in vivo screening model for Chagas disease is predictive, reproducible and adaptable to diverse treatment schedules. It should provide greater assurance that drugs are not advanced prematurely into clinical trial.

1 January 2015 in SLAS Discovery
Verified
Journal Article
Open access
MLMichael D. Lewis
Michael D. Lewis
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
MTMartin Taylor
Martin Taylor
JKJohn Kelly
John Kelly
The protozoan Trypanosoma cruzi is the causative agent of Chagas disease, one of the world's major neglected infections. Although development of improved antiparasitic drugs is considered a priority, there have been no significant treatment advances in the past 40 years. Factors that have limited progress include an incomplete understanding of pathogenesis, tissue tropism, and disease progression. In addition, in vivo models, which allow parasite burdens to be tracked throughout the chronic stage of infection, have been lacking. To address these issues, we have developed a highly sensitive in vivo imaging system based on bioluminescent T. cruzi, which express a red-shifted luciferase that emits light in the tissue-penetrating orange-red region of the spectrum. The exquisite sensitivity of this noninvasive murine model has been exploited to monitor parasite burden in real time throughout the chronic stage, has allowed the identification of the gastrointestinal tract as the major niche of long-term infection, and has demonstrated that chagasic heart disease can develop in the absence of locally persistent parasites. Here, we review the parameters of the imaging system and describe how this experimental model can be incorporated into drug development programs as a valuable tool for assessing efficacy against both acute and chronic T. cruzi infections.

2 April 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
FCFernanda Cristina Costa
Fernanda Cristina Costa
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
SJShiromani Jayawardhana
Shiromani Jayawardhana
SCSimone Guedes Calderano
Simone Guedes Calderano
MLMichael D Lewis
Michael D Lewis
MTMartin Taylor
Martin Taylor
Infection with Trypanosoma cruzi causes Chagas disease, a major public health problem throughout Latin America. There is no vaccine and the only drugs have severe side effects. Efforts to generate new therapies are hampered by limitations in our understanding of parasite biology and disease pathogenesis. Studies are compromised by the complexity of the disease, the long-term nature of the infection, and the fact that parasites are barely detectable during the chronic stage. In addition, functional dissection of T. cruzi biology has been restricted by the limited flexibility of the genetic manipulation technology applicable to this parasite. Here, we describe two technical innovations, which will allow the role of the parasite in disease progression to be better assessed. First, we generated a T. cruzi reporter strain that expresses a fusion protein comprising red-shifted luciferase and green fluorescent protein domains. Bioluminescence allows the kinetics of infection to be followed within a single animal, and specific foci of infection to be pinpointed in excised tissues. Fluorescence can then be used to visualise individual parasites in tissue sections to study host-parasite interactions at a cellular level. Using this strategy, we have been routinely able to find individual parasites within chronically infected murine tissues for the first time. The second advance is the incorporation of a streamlined CRISPR/Cas9 functionality into this reporter strain that can facilitate genome editing using a PCR-based approach that does not require DNA cloning. This system allows the rapid generation of null mutants and fluorescently tagged parasites in a background where the in vivo phenotype can be rapidly assessed. The techniques described here will have multiple applications for studying aspects of T. cruzi biology and Chagas disease pathogenesis previously inaccessible to conventional approaches. The reagents and cell lines have been generated as a community resource and are freely available on request. 5–8 million people in Latin America are infected with the single-cell parasite Trypanosoma cruzi, the causative agent of Chagas disease. Of these, approximately one-third will develop chronic disease pathology, leading to disability and premature death. Only two drugs are available, both of which can have severe side effects. We know relatively little about the chronic phase of this infection because the parasite burden is extremely low, and animal models have limitations. Here, we describe a T. cruzi reporter strain that has been genetically modified to express a fusion protein which is both bioluminescent and fluorescent. These parasites can be monitored throughout the infection, and individual parasites identified in tissue sections from infected mice. This allows us for the first time to analyse host-parasite interactions at a cellular level in the chronic phase of infection. We have also incorporated a streamlined version of the CRISPR/Cas9 genome editing system into the reporter strain. We demonstrated the utility of this system by generating null mutants in the flagellar attachment protein GP72, by replacing the green fluorescent protein with a red fluorescent protein, and by tagging the endogenous protein DNA topoisomerase 1A. This T. cruzi reporter line will significantly enhance our ability to unravel the pathogenesis and immunology of chronic Chagas disease.

25 May 2016 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
MLMichael D. Lewis
Michael D. Lewis
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
MTMartin Taylor
Martin Taylor
SJShiromani Jayawardhana
Shiromani Jayawardhana
JKJohn M. Kelly
John M. Kelly
Host and parasite diversity are suspected to be key factors in Chagas disease pathogenesis. Experimental investigation of underlying mechanisms is hampered by a lack of tools to detect scarce, pleiotropic infection foci. We developed sensitive imaging models to track Trypanosoma cruzi infection dynamics and quantify tissue-specific parasite loads, with minimal sampling bias. We used this technology to investigate cardiomyopathy caused by highly divergent parasite strains in BALB/c, C3H/HeN and C57BL/6 mice. The gastrointestinal tract was unexpectedly found to be the primary site of chronic infection in all models. Immunosuppression induced expansion of parasite loads in the gut and was followed by widespread dissemination. These data indicate that differential immune control of T. cruzi occurs between tissues and shows that the large intestine and stomach provide permissive niches for active infection. The end-point frequency of heart-specific infections ranged from 0% in TcVI-CLBR-infected C57BL/6 to 88% in TcI-JR-infected C3H/HeN mice. Nevertheless, infection led to fibrotic cardiac pathology in all models. Heart disease severity was associated with the model-dependent frequency of dissemination outside the gut and inferred cumulative heart-specific parasite loads. We propose a model of cardiac pathogenesis driven by periodic trafficking of parasites into the heart, occurring at a frequency determined by host and parasite genetics.

17 October 2016 in Scientific Reports
Verified
Journal Article
Open access
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
SJShiromani Jayawardhana
Shiromani Jayawardhana
MLMichael D. Lewis
Michael D. Lewis
KWKaren L. White
Karen L. White
DSDavid M. Shackleford
David M. Shackleford
JKJohn Kelly
John Kelly
The insect-transmitted protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, and infects 5–8 million people in Latin America. Chagas disease is characterised by an acute phase, which is partially resolved by the immune system, but then develops as a chronic life-long infection. There is a consensus that the front-line drugs benznidazole and nifurtimox are more effective against the acute stage in both clinical and experimental settings. However, confirmative studies have been restricted by difficulties in demonstrating sterile parasitological cure. Here, we describe a systematic study of nitroheterocyclic drug efficacy using highly sensitive bioluminescence imaging of murine infections. Unexpectedly, we find both drugs are more effective at curing chronic infections, judged by treatment duration and therapeutic dose. This was not associated with factors that differentially influence plasma drug concentrations in the two disease stages. We also observed that fexinidazole and fexinidazole sulfone are more effective than benznidazole and nifurtimox as curative treatments, particularly for acute stage infections, most likely as a result of the higher and more prolonged exposure of the sulfone derivative. If these findings are translatable to human patients, they will have important implications for treatment strategies.

17 June 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Amanda Fortes FranciscoAmanda Fortes Francisco
Amanda Fortes Francisco
SJShiromani Jayawardhana
Shiromani Jayawardhana
FOFrancisco Olmo
Francisco Olmo
MLMichael D. Lewis
Michael D. Lewis
SWShane R. Wilkinson
Shane R. Wilkinson
JKJohn Kelly
John Kelly
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps in our knowledge of disease pathogenesis, parasite biology and drug activity. Nevertheless, several factors have come together to create a more optimistic scenario. Drug-based research has become more systematic, with increased collaborations between the academic and commercial sectors, often within the framework of not-for-profit consortia. High-throughput screening of compound libraries is being widely applied, and new technical advances are helping to streamline the drug development pipeline. In addition, drug repurposing and optimisation of current treatment regimens, informed by laboratory research, are providing a basis for new clinical trials. Here, we will provide an overview of the current status of Chagas disease drug development, highlight those areas where progress can be expected, and describe how fundamental research is helping to underpin the process.